Mirtazapina Mabo (Mirtazapine)

Mirtazapine works by blocking presynaptic α2‑adrenergic receptors, which increases the release of norepinephrine, and by antagonising postsynaptic 5‑HT2 and 5‑HT3 serotonin receptors, enhancing serotonergic neurotransmission. Its additional histamine H1 antagonism contributes to sedative effects, together supporting mood improvement.

The appropriate dose of Mirtazapina Mabo is determined by the prescribing clinician based on the individual’s clinical condition, response to therapy, and tolerability. Dosage adjustments are made according to professional guidelines and patient-specific factors.

Safety data for mirtazapine in pregnancy and lactation are limited. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss risks and alternatives with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials. After confirmation, the team provides pricing, availability, shipping details and any necessary import documentation.

Mirtazapine belongs to the NaSSA class, differing from selective serotonin reuptake inhibitors (SSRIs) that primarily block serotonin reuptake. Its combined noradrenergic and serotonergic activity often results in stronger sedative and appetite‑stimulating effects, which can be advantageous for patients with insomnia or weight loss, whereas SSRIs tend to have a more activating profile.

Mirtazapina Mabo should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture, direct sunlight and extreme heat. Do not store in the bathroom or near a kitchen sink where humidity is high.

The medication is taken orally, usually as a whole tablet or capsule, with or without food. Patients should swallow the dose whole with a glass of water and follow the prescriber’s instructions regarding timing and any dose adjustments.

Serious adverse reactions include agranulocytosis (a marked decrease in white blood cells), hepatotoxicity (liver injury or enzyme elevation), and the emergence or worsening of suicidal thoughts, especially during early treatment or dose changes. Prompt medical attention is required if any of these events occur.

Mirtazapina Mabo should be avoided in patients with known hypersensitivity to mirtazapine or any of its excipients, those currently taking monoamine oxidase inhibitors (MAOIs), and individuals with severe hepatic impairment unless specifically directed by a specialist. Caution is also advised for patients with a history of bipolar disorder or uncontrolled seizures.